Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retro Biosciences (Retrograde Investments) is developing an in vivo tissue reprogramming gene therapy designed to treat age-related diseases by resetting the epigenetic state of cells. The program utilizes Adeno-Associated Virus (AAV) vectors to deliver specific, though currently undisclosed, reprogramming factors directly to target tissues. This approach aims to induce cellular rejuvenation and restore function in conditions such as osteoarthritis and age-related hearing loss. The therapy is currently in the preclinical stage of development and focuses on partial or transient reprogramming to avoid the induction of pluripotency while restoring youthful cellular phenotypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Retro Biosciences tissue reprogramming program.